---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-018431"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T19:50:44.797359+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio's acoramidis NDA accepted by FDA with PDUFA Nov 29, 2024; secured $1.25B capital; Q4 net loss $168M

## Summary
- Acoramidis NDA accepted by FDA; PDUFA Nov 29, 2024. Phase 3 met primary endpoint (Win Ratio 1.8, p<0.0001).
- Secured up to $1.25B from Blue Owl and CPP Investments: $500M upfront for 5% royalty on acoramidis net sales and $450M credit facility.
- Q4 2023 net loss attributable to common stockholders $168.1M ($0.96 EPS) vs $137.6M ($0.92 EPS) YoY; revenue $1.7M down from $1.9M.
- Cash and cash equivalents $392.6M as of Dec 31, 2023. Full year net loss $643.2M; operating cash used $527.7M.
- Partnership with Kyowa Kirin for infigratinib in Japan: $100M upfront, royalties up to high-twenties percent, milestones.

## SEC filing metadata
- accession: 0000950170-24-018431
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/0000950170-24-018431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/bbio-20240222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-018431
- JSON: https://secwatch.observer/filing/0000950170-24-018431.json
- Plain text: https://secwatch.observer/filing/0000950170-24-018431.txt

## Key facts
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: BridgeBio Pharma, Inc. reported recent business updates and its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/0000950170-24-018431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.